PUSL1 and neoplasm: Strikingly, patients exhibiting elevated levels of PUS1, PUS3, PUSL1, RPUSD1-4, and TRUB2 demonstrated a significantly shorter disease-free survival, as evidenced by combined analysis with tumor disease-free survival data (Fig. 1B and Fig. S1A-L).